AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3304028
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (400 micrograms/day) for twelve weeks
Trial: 27736760
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous (i.v.) omadacycline
Trial: 27736760
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral tablet formulation of omadacycline
Trial: 27736760
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral solution of omadacycline
Trial: 18701647
Drug: CMRI vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMRI vaccine (0.3 to 60 microg followed by a booster dose of 30 microg)
Trial: 18701647
Drug: CMRI vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMRI vaccine (priming doses)
Trial: 18701647
Drug: CMRI vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMRI vaccine (after booster dose)
Trial: 16081857
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin daily (n=17)
Trial: 12160502
Drug: Intrathecal narcotics
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal narcotics (morphine and fentanyl)
Trial: 12160502
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (continuous infusion of bupivacaine and fentanyl)
Trial: 10432467
Drug: Active transdermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal nicotine patch (22 mg/day)
Trial: 10432467
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal nicotine patch
Trial: 10432467
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active and placebo patches
Trial: 7239899
Drug: hand-warming treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hand-warming treatment
Trial: 7239899
Drug: hand-cooling treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hand-cooling treatment
Trial: 24548627
Drug: Anti-TNF-α antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNF-α antibodies (monoclonal and polyclonal)
Trial: 24548627
Drug: Polyclonal antibodies
RxNorm normalized name: Anti-SARS-CoV-2 Polyclonal Antibodies SAB-185
DrugBank: SAB-185 (DB16491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal antibodies or receptor blockers
Trial: 24548627
Drug: Anti-TNF-α therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α therapy in patients with high levels of IL-6 (> 1000 pg/ml)
Trial: 24548627
Drug: Anti-TNF-α therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α therapy in patients with shock
Trial: 12893845
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (0.4 mg/kg)
Trial: 6356318
Drug: sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate (1 g tds 2 h after each meal and 1 g nocte)
Trial: 6356318
Drug: cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (200 mg tds and 400 mg nocte)
Trial: 22198338
Drug: Intravenous topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous topotecan 0.5mg/m(2) and cisplatin 30 mg/m(2) given weekly for 6 weeks with pelvic radiation
Trial: 22198338
Drug: Intravenous topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous topotecan 0.5mg/m(2) and cisplatin 40 mg/m(2) given weekly for 6 weeks with pelvic radiation
Trial: 22198338
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 30 mg/m(2) in combination with topotecan 0.5mg/m(2) and pelvic radiation
Trial: 19443125
Drug: Framycetin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Framycetin 1% cream (Soframycin)
Trial: 17394651
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CRP testing and communication skills training
Trial: 7811016
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g twice daily)
Trial: 2187344
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution amnioinfusion
Trial: 21411800
Drug: Placebo loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo loading dose followed by conivaptan continuous i.v. infusion using the ampul formulation (regimen 1)
Trial: 21411800
Drug: Conivaptan loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan loading dose followed by continuous i.v. infusion using the ampul formulation (regimen 2)
Trial: 21411800
Drug: Placebo loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo loading dose followed by conivaptan continuous i.v. infusion using the premixed formulation (regimen 3)
Trial: 21411800
Drug: Conivaptan loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan loading dose followed by continuous i.v. infusion using the premixed formulation (regimen 4)
Trial: 11465987
Drug: Bolus-Continuous (BC-)
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus-Continuous (BC-) group (3 mg base rate/h, 1 mg bolus, 20 min lock out)
Trial: 11465987
Drug: Bolus (B-)
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus (B-) group (no base rate, 1 mg bolus, 10 min lock out)
Trial: 9596316
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (500 microg) before suctioning
Trial: 29757375
Drug: Tablet-based consent
RxNorm normalized name: amlodipine / celecoxib Oral Tablet [Consensi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based consent process
Trial: 28043176
Drug: Control (directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (directly observed treatment with adherence counseling alone)
Trial: 22031267
Drug: Myo-inositol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (0.6 g in soft gel capsule or 2 g in powder)
Trial: 18452885
Drug: Ivermectin 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.1, 0.2, 0.2, and 0.2 mg/kg
Trial: 18452885
Drug: Albendazole 6.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 6.7 mg/kg
Trial: 17254459
Drug: BTX‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A injection guided by electric stimulation
Trial: 31300331
Drug: Four RTS,S/AS01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four RTS,S/AS01 doses (four‐dose group)
Trial: 31300331
Drug: Three RTS,S/AS01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three RTS,S/AS01 doses (three‐dose group)
Trial: 31300331
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (four comparator doses)
Trial: 24002495
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg selenized yeast daily for 48 months)
Trial: 24002495
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 48 months)
Trial: 21148043
Drug: Tasocitinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasocitinib (100 mg)
Trial: 17352966
Drug: Acupressure using
RxNorm normalized name: ACUPRESSURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure using wristbands (Sea-Band) for 5 days post-chemotherapy
Trial: 10097483
Drug: School and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School and home-based drug prevention program
Trial: 31126960
Drug: Chemotherapy (Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Arm C)
Trial: 23740211
Drug: Topical spray
RxNorm normalized name: Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spray (MedSpray™ tinea pedis 1% w/w)
Trial: 23740211
Drug: Topical solution
RxNorm normalized name: Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution (Lamisil® Once 1% w/w)
Trial: 21041163
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride (3.75 g)
Trial: 16898431
Drug: OASIS Mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OASIS Mouth Moisturizing Spray
Trial: 15037411
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg; n = 18)
Trial: 15037411
Drug: Continuous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19)
Trial: 9387952
Drug: Nebulized morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized morphine 20 mg
Trial: 9387952
Drug: Nebulized morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized morphine 40 mg
Trial: 8133853
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (900 mg/kg for 501-1000 g; 700 mg/kg for 1001-1500 g), repeated every 14 days until certain criteria were met
Trial: 8133853
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo infusions during phase 1, none during phase 2)
Trial: 2683557
Drug: Nimodipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (40 mg t.i.d. for 28 days)
Trial: 27175447
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 12 weeks
Trial: 29540864
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine (GEXR)
Trial: 26778524
Drug: Atorvastatin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 60 mg (AT 60)
Trial: 26778524
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg (AT 20)
Trial: 26778524
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (AT 60 mg and AT 20 mg)
Trial: 23158914
Drug: Serum total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum total bilirubin (TBil) levels stratified into three groups: lower-level group (TBil ≤ 12.8 mmol/L), moderate-level group (TBil > 12.8 ∼ 18.2 mmol/L), higher-level group (TBil > 18.2 mmol/L)
Trial: 16205916
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg t.i.d.)
Trial: 16205916
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg t.i.d.)
Trial: 10629018
Drug: Itraconazole cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole cyclodextrin solution
Trial: 6395273
Drug: Cefonicid (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1.0 g every 24 hr)
Trial: 6395273
Drug: Cefamandole (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1.0 g iv every 6 hr)
Trial: 30128710
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (n=284)
Trial: 30128710
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n=286)
Trial: 26615509
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of meloxicam
Trial: 26615509
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of diclofenac
Trial: 24216088
Drug: L-dopa with
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa with benserazide
Trial: 22348456
Drug: Plant-extractive compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-extractive compound
Trial: 20662070
Drug: AZD5672 (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5672 (20, 50, 100, or 150 mg orally, once daily)
Trial: 20662070
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg subcutaneously, once weekly)
Trial: 15770222
Drug: Oligofructose (OFS)
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (OFS) 16 g/day for 8 weeks
Trial: 10395619
Drug: Oligofructose (Raftilose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (Raftilose P95) 2 g three times daily for 4 weeks
Trial: 10395619
Drug: Sucrose 1
RxNorm normalized name: Sucrose 1-fructosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 1 g three times daily for 4 weeks (Control)
Trial: 7671182
Drug: Diltiazem (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (calcium blocker)
Trial: 7671182
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium blocker (control)
Trial: 2019378
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of single-agent cefotaxime, 2 g IV every 8 hours
Trial: 2019378
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of single-agent cefotaxime, 2 g IV every 8 hours
Trial: 7082501
Drug: Histamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine infusion with cimetidine
Trial: 30106876
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment with a 1-kg gain in body weight
Trial: 30106876
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment with a 1-point increase in percentage of body fat
Trial: 23343614
Drug: Doxazosin 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 0.03 mg/kg/d once daily before bed (group 2)
Trial: 23343614
Drug: Ibuprofen 20
RxNorm normalized name: ibuprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 20 mg/kg/d divided into 2 doses for pain control (group 1)
Trial: 1603535
Drug: Subconjunctival 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival 5-fluorouracil (5-FU) injections, 4 to 6 injections over 10 days postoperatively.
Trial: 1603535
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with 5-fluorouracil (5-FU).
Trial: 24237113
Drug: Brief Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Symptom Inventory (BSI) administered at 30, 90, and 180 days postinjury
Trial: 23009189
Drug: Multi-modal exercise
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal exercise program (twice weekly, 60 minute classes for 16 weeks)
Trial: 18986412
Drug: Nesiritide administration
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide administration
Trial: 15121562
Drug: Soy-based food
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-based food supplement (n = 9) for 5 consecutive evenings
Trial: 15121562
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (n = 19) for 5 consecutive evenings
Trial: 11509866
Drug: co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of GH and prednisolone
Trial: 11509866
Drug: oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral prednisolone 50 mg/day
Trial: 2824861
Drug: Adjuvant medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant medroxyprogesterone acetate (500 mg, 3 times a week for 1 year)
Trial: 30138013
Drug: CBT or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT or COMB treatment
Trial: 30138013
Drug: Treatment responders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment responders and remitters
Trial: 26349936
Drug: High NaCl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NaCl diet (32 g/d) supplemented with 90 mmol KHCO3/day for 10 days
Trial: 26349936
Drug: High NaCl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NaCl diet (31 g/day)
Trial: 26349936
Drug: Low NaCl
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NaCl diet (3 g/day) with acidified diet
Trial: 22782948
Drug: pegIFN-α2a/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFN-α2a/ribavirin therapy
Trial: 17924894
Drug: Midazolam (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (up to 5 mg)
Trial: 9450712
Drug: Paroxetine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine, 20 to 30 mg/d
Trial: 9450712
Drug: Nortriptyline, targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline, targeted to a therapeutic plasma level of 190 to 570 nmol/L (50‐150 ng/mL)
Trial: 25713485
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus metronidazole in combination with scaling and root planning (SRP)
Trial: 23410871
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg before emergency PCI, followed by atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks (Group A)
Trial: 23410871
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks without pre-PCI loading dose (Group B)
Trial: 23410871
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg for 24 weeks only post-PCI (Group C)
Trial: 21639907
Drug: Infliximab alone
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab alone (5 mg/kg at weeks 0, 2, 6, 12, and 18)
Trial: 21639907
Drug: Infliximab combined
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab combined with Methotrexate (10 mg/week)
Trial: 3429863
Drug: Nicardipine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 50 mg twice daily for 3 weeks
Trial: 8085125
Drug: 50% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% glucose solution
Trial: 27927030
Drug: Balance specific
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance specific rehabilitation, 20 treatment sessions
Trial: 27927030
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatments to reduce limitations at activity and body function level, 20 treatment sessions
Trial: 25873634
Drug: ETN 50
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 50 mg QW + MTX
Trial: 25873634
Drug: ETN 25
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 25 mg QW + MTX
Trial: 22752489
Drug: Donepezil (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks)
Trial: 8673350
Drug: Psychopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological treatment (alprazolam + sulpiride)
Trial: 8673350
Drug: Psychopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological treatment (alprazolam + sulpiride) plus social support by volunteers (SSV)
Trial: 8673350
Drug: Psychopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological treatment (alprazolam + sulpiride) plus structured psychotherapy (autogenous training)
Trial: 28847527
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (IVAA) administered simultaneously with modulated electrohyperthermia (mEHT)